Neuropathix, Inc (NPTX)
| Market Cap | 14.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.54M |
| Shares Out | 87.29M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $0.1700 |
| Previous Close | $0.1650 |
| Change ($) | 0.0050 |
| Change (%) | 3.03% |
| Day's Open | 0.1633 |
| Day's Range | 0.1633 - 0.1714 |
| Day's Volume | 86,029 |
| 52-Week Range | 0.1010 - 0.5450 |
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that it...
DOYLESTOWN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced the publicati...
DOYLESTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (OTCQB: NPTX), (the “Company” or "Neuropathix"), a socially responsible pain management life sciences company, announced today that i...
About NPTX
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild trauma... [Read more...]
| Industry Biotechnology | Founded 2010 |
| Stock Exchange OTCMKTS | Ticker Symbol NPTX |